· Increasing momentum as we expanded our portfolio of investments, built the team and fostered new partnerships · Three new portfolio company investments and two existing portfolio company financing extensions · First ever Novo Nordisk and Novo Holdings Partnering Day focusing on Cardio Metabolic disease Copenhagen, Denmark, 3 April 2024 – Novo Holdings Asia Investments team today publishes its […]
AstraZeneca buys Novo Holdings portfolio company Amolyt in potential $1bn+ deal Novo Holdings A/S and Sofinnova Partners, two leading life sciences investors, made headlines on Thursday when portfolio company Amolyt Pharma entered into a definitive agreement to be acquired by AstraZeneca at a purchase price of US$800 million upfront and a potential milestone payment of […]
Established the Novo Holdings Bioindustrial Investments team, now overseeing a dynamic portfolio of 23 companies. Made substantial investments, solidifying Novo Holdings’ position as one of the world’s foremost active investors in the bioindustrial sector. Welcomed three innovative companies to our portfolio. Achieved significant milestones with existing portfolio companies, showcasing strong progress and commitment to sustainable […]
Financing to advance first platform designed to reprogram cancer cells into immune cells as pan-tumoral cancer treatment Novo Holdings participation follows earlier investment and incubation through seed phase Financing co-led by RV Invest and Johnson & Johnson Innovation, joined by existing investors Boehringer Ingelheim Venture Fund and Industrifonden COPENHAGEN – March 14th, 2024 – Novo Holdings, […]
Copenhagen, Denmark – Novo Holdings today announced its financial results for 2023*. Strong Investment Portfolio performance, and growth of the Novo Group companies drive Total Income and Investment Returns to DKK 31 billion (€4.2 billion) for 2023, up from DKK 3 billion (€0.4 billion) in 2022. The Investment Portfolio generated a return of 9.4%, compared to […]
